{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:33:18Z","timestamp":1787509998924,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015235","name":"Supernus Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40268-026-00543-y","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:26:50Z","timestamp":1775194010000},"page":"129-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT2C, 5-HT2B, and 5-HT7 Receptor Binding at Therapeutically Relevant Concentrations"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-0744","authenticated-orcid":false,"given":"Jennie","family":"Garcia-Olivares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittney","family":"Yegla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"543_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1021\/jm00240a009","volume":"18","author":"DT Greenwood","year":"1975","unstructured":"Greenwood DT, Mallion KB, Todd AH, Turner RW. 2-Aryloxymethyl-2,3,5,6-tetrahydro-1,4-oxazines, a new class of antidepressants. J Med Chem. 1975;18:573\u20137.","journal-title":"J Med Chem"},{"key":"543_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/238157a0","volume":"238","author":"KB Mallion","year":"1972","unstructured":"Mallion KB, Todd AH, Turner RW, et al. 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride, a potential psychotropic agent. Nature. 1972;238:157\u20138.","journal-title":"Nature"},{"key":"543_CR3","first-page":"18","volume":"3","author":"D Greenwood","year":"1975","unstructured":"Greenwood D. Animal pharmacology of viloxazine (Vivalan). J Int Med Res. 1975;3:18\u201330.","journal-title":"J Int Med Res"},{"key":"543_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1139\/y76-069","volume":"54","author":"W Lippman","year":"1976","unstructured":"Lippman W, Pugsley TA. Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities. Can J Physiol Pharmacol. 1976;54:494\u2013509.","journal-title":"Can J Physiol Pharmacol"},{"key":"543_CR5","doi-asserted-by":"crossref","first-page":"460p","DOI":"10.1111\/j.1476-5381.1977.tb06974.x","volume":"59","author":"RS Jones","year":"1977","unstructured":"Jones RS, Roberts MH. Effects of viloxazine on cortical neurone responses to monoamines and acetylcholine [proceedings]. Br J Pharmacol. 1977;59:460p.","journal-title":"Br J Pharmacol"},{"key":"543_CR6","first-page":"403p","volume":"62","author":"RS Jones","year":"1978","unstructured":"Jones RS, Roberts MH. Potentiation of monoamine responses of denervated cells by a noradrenaline uptake inhibitor (viloxazine) [proceedings]. Br J Pharmacol. 1978;62:403p\u20134p.","journal-title":"Br J Pharmacol"},{"key":"543_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1476-5381.1979.tb07858.x","volume":"65","author":"RS Jones","year":"1979","unstructured":"Jones RS, Roberts MH. Potentiation of responses to monoamines by antidepressants after destruction of monoamine afferents. Br J Pharmacol. 1979;65:501\u201310.","journal-title":"Br J Pharmacol"},{"key":"543_CR8","unstructured":"STRATTERA (atomoxetine). Prescribing information. Lilly USA; 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/021411s050lbl.pdf. Accessed 23 Oct 2025."},{"key":"543_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/JEP.S256586","volume":"12","author":"C Yu","year":"2020","unstructured":"Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285\u2013300.","journal-title":"J Exp Pharmacol"},{"key":"543_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0022-3565(25)33153-8","volume":"222","author":"DT Wong","year":"1982","unstructured":"Wong DT, Threlkeld PG, Best KL, Bymaster FP. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther. 1982;222:61\u20135.","journal-title":"J Pharmacol Exp Ther"},{"key":"543_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/JEP.S433524","volume":"16","author":"J Garcia-Olivares","year":"2024","unstructured":"Garcia-Olivares J, Yegla B, Bymaster FP, et al. Viloxazine increases extracellular concentrations of norepinephrine, dopamine, and serotonin in the rat prefrontal cortex at doses relevant for the treatment of attention-deficit\/hyperactivity disorder. J Exp Pharmacol. 2024;16:13\u201324.","journal-title":"J Exp Pharmacol"},{"key":"543_CR12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1124\/jpet.107.119404","volume":"321","author":"P Bonaventure","year":"2007","unstructured":"Bonaventure P, Kelly L, Aluisio L, et al. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther. 2007;321:690\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"543_CR13","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099\u2013108.","journal-title":"Biochem Pharmacol"},{"key":"543_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/9781118788523","volume-title":"Blood\u2013brain barrier in drug discovery: optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs","author":"L Di","year":"2015","unstructured":"Di L, Kerns EH. Blood\u2013brain barrier in drug discovery: optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs. 1st ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2015."},{"key":"543_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/0269881117742101","volume":"32","author":"L Settimo","year":"2018","unstructured":"Settimo L, Taylor D. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. J Psychopharmacol. 2018;32:96\u2013104.","journal-title":"J Psychopharmacol"},{"key":"543_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","volume":"340","author":"M Tatsumi","year":"1997","unstructured":"Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249\u201358.","journal-title":"Eur J Pharmacol"},{"key":"543_CR17","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/jcph.1940","volume":"61","author":"A Nasser","year":"2021","unstructured":"Nasser A, Gomeni R, Wang Z, et al. Population pharmacokinetics of viloxazine extended-release capsules in pediatric subjects with attention deficit\/hyperactivity disorder. J Clin Pharmacol. 2021;61:1626\u201337.","journal-title":"J Clin Pharmacol"},{"key":"543_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0014-2999(78)90291-1","volume":"52","author":"TP Blackburn","year":"1978","unstructured":"Blackburn TP, Foster GA, Greenwood DT, Howe R. Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo. Eur J Pharmacol. 1978;52:367\u201374.","journal-title":"Eur J Pharmacol"},{"key":"543_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0893-133X(02)00346-9","volume":"27","author":"FP Bymaster","year":"2002","unstructured":"Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit\/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699\u2013711.","journal-title":"Neuropsychopharmacology"},{"key":"543_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0028-3908(78)90018-7","volume":"17","author":"IL Martin","year":"1978","unstructured":"Martin IL, Baker GB, Mitchell PR. The effect of viloxazine hydrochloride on the transport of noradrenaline, dopamine, 5-hydroxytryptamine and gamma-amino-butyric acid in rat brain tissue. Neuropharmacology. 1978;17:421\u20133.","journal-title":"Neuropharmacology"},{"key":"543_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00003495-197713060-00001","volume":"13","author":"RM Pinder","year":"1977","unstructured":"Pinder RM, Brogden RN, Speight TM, Avery GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13:401\u201321.","journal-title":"Drugs"},{"key":"543_CR22","first-page":"287","volume":"31","author":"DT Greenwood","year":"1982","unstructured":"Greenwood DT. Viloxazine and neurotransmitter function. Adv Biochem Psychopharmacol. 1982;31:287\u2013300.","journal-title":"Adv Biochem Psychopharmacol"},{"key":"543_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1523\/JNEUROSCI.22-02-00389.2002","volume":"22","author":"JA Mor\u00f3n","year":"2002","unstructured":"Mor\u00f3n JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002;22:389\u201395.","journal-title":"J Neurosci"},{"key":"543_CR24","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/00498254.2020.1767319","volume":"50","author":"C Yu","year":"2020","unstructured":"Yu C. Metabolism and in vitro drug\u2013drug interaction assessment of viloxazine. Xenobiotica. 2020;50:1285\u2013300.","journal-title":"Xenobiotica"},{"key":"543_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40261-025-01473-4","volume":"45","author":"MB Solomon","year":"2025","unstructured":"Solomon MB, Yegla B, Newcorn JH, Maletic V, Rubin J, Robbins TW. Revisiting the role of serotonin in attention-deficit hyperactivity disorder: new insights from preclinical and clinical studies. Clin Drug Investig. 2025;45:701\u201342.","journal-title":"Clin Drug Investig"},{"key":"543_CR26","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00213-017-4545-5","volume":"234","author":"JM Palacios","year":"2017","unstructured":"Palacios JM, Pazos A, Hoyer D. A short history of the 5-HT(2C) receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology. 2017;234:1395\u2013418.","journal-title":"Psychopharmacology (Berl.)"},{"key":"543_CR27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2174\/1568026619666190709101449","volume":"19","author":"EA Wold","year":"2019","unstructured":"Wold EA, Wild CT, Cunningham KA, Zhou J. Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development. Curr Top Med Chem. 2019;19:1381\u201398.","journal-title":"Curr Top Med Chem"},{"key":"543_CR28","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1177\/0269881117735797","volume":"31","author":"GA Higgins","year":"2017","unstructured":"Higgins GA, Zeeb FD, Fletcher PJ. Role of impulsivity and reward in the anti-obesity actions of 5-HT(2C) receptor agonists. J Psychopharmacol. 2017;31:1403\u201318.","journal-title":"J Psychopharmacol"},{"key":"543_CR29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41386-022-01484-1","volume":"47","author":"B Yegla","year":"2022","unstructured":"Yegla B, Garcia-Olivares J, Zweibaum D, Bymaster FP, Yu C. Viloxazine increases interstitial levels of norepinephrine and serotonin in a dose dependent fashion in rat medial prefrontal cortex. Neuropsychopharmacology. 2022;47:63\u2013219 (American College of Neuropsychopharmacology Meeting abstract P167).","journal-title":"Neuropsychopharmacology"},{"key":"543_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s40263-022-00938-w","volume":"36","author":"A Nasser","year":"2022","unstructured":"Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder. CNS Drugs. 2022;36:897\u2013915.","journal-title":"CNS Drugs"},{"key":"543_CR31","unstructured":"Viloxazine ER for ADHD reduces weight among adults with overweight, obesity. Psychiatry Advisor. 2025. https:\/\/www.psychiatryadvisor.com\/reports\/viloxazine-er-weight-loss-adhd\/. Accessed 15 July 2025."},{"key":"543_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00213-009-1626-0","volume":"206","author":"PB Hedlund","year":"2009","unstructured":"Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology. 2009;206:345\u201354.","journal-title":"Psychopharmacology (Berl.)"},{"key":"543_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1021\/acschemneuro.8b00283","volume":"10","author":"KM Blattner","year":"2019","unstructured":"Blattner KM, Canney DJ, Pippin DA, Blass BE. Pharmacology and therapeutic potential of the 5-HT(7) receptor. ACS Chem Neurosci. 2019;10:89\u2013119.","journal-title":"ACS Chem Neurosci"},{"key":"543_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.neuropharm.2016.05.024","volume":"109","author":"C Devroye","year":"2016","unstructured":"Devroye C, Cathala A, Haddjeri N, et al. Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: new opportunities for the treatment of schizophrenia. Neuropharmacology. 2016;109:59\u201368.","journal-title":"Neuropharmacology"},{"key":"543_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2017.07.014","volume":"181","author":"C Devroye","year":"2018","unstructured":"Devroye C, Cathala A, Piazza PV, Spampinato U. The central serotonin(2B) receptor as a new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders: rationale and current status of research. Pharmacol Ther. 2018;181:143\u201355.","journal-title":"Pharmacol Ther"},{"key":"543_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1087054719836159","volume":"24","author":"JK Johnson","year":"2020","unstructured":"Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24:348\u201358.","journal-title":"J Atten Disord"},{"key":"543_CR37","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","volume":"42","author":"A Nasser","year":"2020","unstructured":"Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children. Clin Ther. 2020;42:1452\u201366.","journal-title":"Clin Ther"},{"key":"543_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.neuroimage.2010.09.040","volume":"56","author":"JD Gallezot","year":"2011","unstructured":"Gallezot JD, Weinzimmer D, Nabulsi N, et al. Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: studies with atomoxetine in non-human primates. Neuroimage. 2011;56:268\u201379.","journal-title":"Neuroimage"},{"key":"543_CR39","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.neuroimage.2013.08.001","volume":"86","author":"YS Ding","year":"2014","unstructured":"Ding YS, Naganawa M, Gallezot JD, et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: implications on treatment of depression and ADHD. Neuroimage. 2014;86:164\u201371.","journal-title":"Neuroimage"},{"key":"543_CR40","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.biopsych.2010.06.017","volume":"68","author":"J Hannestad","year":"2010","unstructured":"Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry. 2010;68:854\u201360.","journal-title":"Biol Psychiatry"},{"key":"543_CR41","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/syn.21538","volume":"66","author":"FP Bymaster","year":"2012","unstructured":"Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse. 2012;66:522\u201332.","journal-title":"Synapse"},{"key":"543_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1471-4159.2010.06750.x","volume":"114","author":"K Koda","year":"2010","unstructured":"Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem. 2010;114:259\u201370.","journal-title":"J Neurochem"},{"key":"543_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/JCP.0000000000001575","volume":"42","author":"LA Adler","year":"2022","unstructured":"Adler LA, Adams J, Madera-McDonough J, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit\/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022;42:429\u201339.","journal-title":"J Clin Psychopharmacol"},{"key":"543_CR44","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m14934","volume":"84","author":"CBH Surman","year":"2023","unstructured":"Surman CBH, Walsh DM, Horick N, DiSalvo M, Vater CH, Kaufman D. Solriamfetol for attention-deficit\/hyperactivity disorder in adults: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2023;84:23m14934.","journal-title":"J Clin Psychiatry"},{"key":"543_CR45","unstructured":"Center for Drug Evaluation and Research Memorandum, United States Food and Drug Administration. Review of revised label. Qelbree (viloxazine extended-release capsules), March 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/211964Orig1s000OtherR.pdf. Accessed 15 July 2025."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00543-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00543-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00543-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:09:48Z","timestamp":1776071388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-026-00543-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1007\/s40268-026-00543-y","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Medical writing support, funded by Supernus, was provided by Callie A. S. Corsa, PhD, ISMPP CMPP\n                      TM\n                      , and Lisa M. Pitchford, PhD, ISMPP CMPP\n                      TM\n                      , of JB Ashtin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical writing, editorial, and other assistance"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Animal experimentation for this study was conducted in accordance with the UK Animals (Scientific Procedures) Act 1986 and the transposed EU directive 2010\/63\/EU. All procedures were approved by the Animal Ethical Review Committee of Imperial College.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"JG-O, BY, JK, CY, and JR are employees of Supernus Pharmaceuticals, Inc.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"JG-O, BY, CY, and JR contributed to the study concept and design. JG-O contributed to statistical analysis. JG-O, BY, JK, CY, and JR contributed to data interpretation. All authors have read and approved the final version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}